Aims: To investigate the major aspects of mortality in patients with noninsulin-treated type 2 diabetes mellitus (T2DM), from 1942 till 2000.
Subjects And Methods: We performed a retrospective study in 9698 noninsulin-treated T2DM patients, 5001 (51.6%) males and 4695 (48.4%) females, registered in Bucharest Diabetes Center and deceased between 1943 and 2000. For each patient the age at diabetes onset, disease duration, age at death, cause of death, sex, height and weight were recorded.
Results: The mean age at diabetes onset was 58.3 +/- 9.1 years in 1943-1960 period (no significant differences by sex) and 60.6 +/- 10.3 years in 1981-2000 (59.3 +/- 10.3 years in males and 61.8 +/- 10.1 years in females, p < 0.01 vs. males). The mean disease duration at death was 7.7 +/- 5.2 years in 1943-1960 period (no significant differences by sex) and 11.3 +/- 8.1 years in 1981-2000 (11.9 +/- 8.4 years in males and 10.7 +/- 7.6 years in females, p < 0.01 vs. males). The mean age at death was 66 +/- 9.8 years in 1943-1960 period (no significant differences by sex) and 71.9 +/- 9.7 years in 1981-2000 (71.2 +/- 9.9 years in males and 72.5 +/- 9.5 years in females, p < 0.01 vs. males). In the Cox regression analysis, an increase in mortality was associated with the masculine sex--9.6% (CI 95% 1-19%, p = 0.028) compared with feminine sex; 1 year increase in age at onset--4.8% (CI 95% 4.3-5.3%, p < 0.01); 1 kg/m2 increase in body mass index--2.9% (CI 95% 1.9-3.8%, p < 0.01); 1 mg/dl increase in mean fasting blood glucose--0.1% (CI 95% 0-0.2%, p = 0.025). The major causes of death in noninsulin-treated T2DM patients in the 1981-2000 period were: ischemic heart disease (53.8%), stroke (14.4%), cancer (9%), digestive diseases (6.3%), diabetes (5.3%), end stage renal disease (4.6%), infections (2.7%), diabetes coma (2.2%) and others (1.7%).
Conclusions: There is a statistically significant increase in the proportion of death caused by ischemic heart disease, while infections significantly decreased in importance during the study period. The masculine sex, age at onset, mean fasting blood glucose and body mass index were all significant predictors of mortality in the Cox regression analysis, adjusted for the year of death.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.
Neurology
August 2015
From Janssen Alzheimer Immunotherapy Research & Development, LLC (E.L., R.M., P.C., K.M.G., J.D., Y.L., I.C.T., S.B., E.Y., H.R.B.), South San Francisco, CA; Janssen Pharmaceutical (M.E.S.), Beerse, NV; Brigham & Women's Hospital (R.S.), Boston, MA; University of Michigan (R.K.), Ann Arbor; University of Pittsburgh (N.S.M., W.E.K., C.A.M.), PA; Butler Hospital (S.S.), Providence, RI; UCL Institute of Neurology (N.C.F.), London, UK; IXICO plc (D.L.H., A.S.L.), London, UK; Pfizer Inc. (B.T.W.), Groton, CT; Pfizer Inc. (K.B.), Collegeville, PA; Global R&D Partners, LLC (M.G.), San Diego, CA; and University of California (M.G.), San Diego.
Objective: To evaluate the effects of bapineuzumab on brain β-amyloid (Aβ) burden using (11)C-Pittsburgh compound B ((11)C-PiB)-PET.
Methods: Two phase 3 clinical trials, 1 each in apolipoprotein APOE ε4 carriers and noncarriers, were conducted in patients with mild to moderate Alzheimer disease dementia. Bapineuzumab, an anti-Aβ monoclonal antibody, or placebo, was administered by IV infusion every 13 weeks for 78 weeks.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
N Engl J Med
January 2014
From Butler Hospital, Providence, RI (S.S.); Brigham and Women's Hospital, Boston (R.S.); University College London, Institute of Neurology, London (N.C.F.); University of Göteborg, Sahlgrenska University Hospital, Mölndal, Sweden (K.B.); University of Pittsburgh, Pittsburgh (W.K.); Veterans Affairs Medical Center, Seattle (M.R.); Cleo Roberts Center for Clinical Research/Sun Health Research Institute, Sun City, AZ (M.S.); Columbia University (L.S.H.) and New York University Langone Medical Center (S.F.), New York; University of Rochester School of Medicine and Dentistry, Rochester, NY (A.P.P.); Janssen Alzheimer Immunotherapy Research and Development, South San Francisco, CA (M.R., N.K., B.N., V.G., M.M., D.W., Y.L., I.C.T., E.L., E.Y., H.R.B.); Janssen Research and Development, Titusville, NJ (J.L.); Global R&D Partners and the University of California, San Diego - both in San Diego (M.G.); and Pfizer, Collegeville, PA (R.B.).
Background: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease.
Methods: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying by study, was administered by intravenous infusion every 13 weeks for 78 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!